We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AcelRx Pharmaceuticals Draws Warning Letter for Misleading Claims
AcelRx Pharmaceuticals Draws Warning Letter for Misleading Claims
The FDA’s Office of Prescription Drug Promotion (OPDP) issued a warning letter to AcelRx Pharmaceuticals over false and misleading claims it made for its oral opioid Dsuvia (sufentanil).